{"id":59144,"date":"2026-03-10T13:24:17","date_gmt":"2026-03-10T05:24:17","guid":{"rendered":"https:\/\/flcube.com\/?p=59144"},"modified":"2026-03-10T13:24:18","modified_gmt":"2026-03-10T05:24:18","slug":"hengruis-hrs9531-wins-nmpa-approval-for-ckd-trial-dual-gipr-glp-1r-agonist-expands-beyond-diabetes-and-obesity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59144","title":{"rendered":"Hengrui&#8217;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that <strong>HRS9531<\/strong>, a <strong>novel dual agonist targeting GIPR and GLP-1R<\/strong>, has received <strong>NMPA clinical trial approval<\/strong> for the treatment of <strong>chronic kidney disease (CKD)<\/strong>. The approval marks a <strong>strategic expansion<\/strong> of Hengrui&#8217;s <strong>globally proprietary incretin platform<\/strong> beyond its established <strong>glycemic control and weight management<\/strong> applications into <strong>renal protection<\/strong>, positioning the candidate as a <strong>potential multi-indication metabolic-renal therapy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HRS9531<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Dual GIPR\/GLP-1R agonist (small molecule\/peptide hybrid)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Chronic kidney disease (CKD)<\/td><\/tr><tr><td><strong>Prior Indications<\/strong><\/td><td>Type 2 diabetes, obesity (Phase II\/III ongoing)<\/td><\/tr><tr><td><strong>IP Status<\/strong><\/td><td>Global proprietary intellectual property rights<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>9\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>HRS9531 Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Targets<\/strong><\/td><td>Gastric inhibitory polypeptide receptor (GIPR) + Glucagon-like peptide-1 receptor (GLP-1R)<\/td><\/tr><tr><td><strong>Mechanism Class<\/strong><\/td><td>Dual incretin agonist (similar to tirzepatide)<\/td><\/tr><tr><td><strong>Metabolic Effects<\/strong><\/td><td>\u2022 Glucose regulation<br>\u2022 Lipid metabolism optimization<br>\u2022 Appetite suppression<br>\u2022 Insulin sensitivity enhancement<\/td><\/tr><tr><td><strong>Clinical Outcomes<\/strong><\/td><td>Improved glycemic control; effective weight reduction<\/td><\/tr><tr><td><strong>Renal Rationale<\/strong><\/td><td>GLP-1R activation reduces glomerular hyperfiltration; GIPR modulation may provide additional renoprotection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>CKD Therapeutic Hypothesis:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hemodynamic:<\/strong> GLP-1R agonism reduces intraglomerular pressure and albuminuria<\/li>\n\n\n\n<li><strong>Metabolic:<\/strong> Improved glycemic\/lipid control slows diabetic nephropathy progression<\/li>\n\n\n\n<li><strong>Anti-inflammatory:<\/strong> Dual incretin signaling may reduce renal fibrosis and inflammation<\/li>\n\n\n\n<li><strong>Weight Benefit:<\/strong> Obesity-driven CKD (epidemic in China) addressed through metabolic component<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-competitive-landscape\">Strategic Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>CKD Market Size<\/strong><\/td><td>China: 100+ million CKD patients; diabetic nephropathy accounts for 40-50% of cases<\/td><\/tr><tr><td><strong>GLP-1 in Nephrology<\/strong><\/td><td>Semaglutide (FLOW trial) demonstrated 24% CKD progression risk reduction; regulatory filings pending globally<\/td><\/tr><tr><td><strong>Dual Agonist Advantage<\/strong><\/td><td>GIPR\/GLP-1R co-activation potentially superior to GLP-1R alone for renal outcomes (emerging evidence)<\/td><\/tr><tr><td><strong>Hengrui Positioning<\/strong><\/td><td>First domestic dual incretin to enter CKD trials; challenges Eli Lilly&#8217;s tirzepatide for China market leadership<\/td><\/tr><tr><td><strong>Global Ambitions<\/strong><\/td><td>U.S.\/EU IND preparation ongoing; CKD indication may support differentiated labeling vs. diabetes\/obesity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>CKD Status<\/th><th>HRS9531 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Novo Nordisk<\/strong><\/td><td>Ozempic\/Wegovy (semaglutide)<\/td><td>GLP-1R agonist<\/td><td>FLOW trial positive; label expansion pending<\/td><td>Dual GIPR\/GLP-1R mechanism<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>Mounjaro\/Zepbound (tirzepatide)<\/td><td>GIPR\/GLP-1R dual agonist<\/td><td>SURPASS-CVOT renal data emerging<\/td><td>China-first CKD development; domestic manufacturing cost advantage<\/td><\/tr><tr><td><strong>Hengrui<\/strong><\/td><td><strong>HRS9531<\/strong><\/td><td><strong>Dual GIPR\/GLP-1R agonist<\/strong><\/td><td><strong>Phase I-ready (CKD)<\/strong><\/td><td><strong>Globally proprietary IP; China market priority<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I (CKD)<\/strong><\/td><td>2026-2027<\/td><td>Safety, tolerability, albuminuria reduction biomarkers<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2028<\/td><td>Dose-ranging, eGFR slope, composite renal endpoints<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2028-2030<\/td><td>Hard renal outcomes (ESRD, doubling of creatinine, renal death)<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2030-2031<\/td><td>China NDA as first dual incretin CKD therapy; U.S.\/EU follow-on<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, renal protective efficacy, and competitive positioning for HRS9531 in chronic kidney disease. Actual results may differ due to trial outcomes, regulatory requirements, and competitive dynamics with established GLP-1R agonists.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900850_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030900850_c.\"><\/object><a id=\"wp-block-file--media-12ae4b1b-df1e-4ad8-8cce-40a83a4bfda3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900850_c.pdf\">2026030900850_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900850_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-12ae4b1b-df1e-4ad8-8cce-40a83a4bfda3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2586,4228,852],"class_list":["post-59144","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui&#039;s globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59144\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui&#039;s globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59144\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T05:24:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T05:24:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\\\/GLP-1R Agonist Expands Beyond Diabetes and Obesity\",\"datePublished\":\"2026-03-10T05:24:17+00:00\",\"dateModified\":\"2026-03-10T05:24:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59144#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59144\",\"name\":\"Hengrui's HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\\\/GLP-1R Agonist Expands Beyond Diabetes and Obesity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-10T05:24:17+00:00\",\"dateModified\":\"2026-03-10T05:24:18+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui's globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59144\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59144#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\\\/GLP-1R Agonist Expands Beyond Diabetes and Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui's globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59144","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui's globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.","og_url":"https:\/\/flcube.com\/?p=59144","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T05:24:17+00:00","article_modified_time":"2026-03-10T05:24:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59144#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59144"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity","datePublished":"2026-03-10T05:24:17+00:00","dateModified":"2026-03-10T05:24:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59144"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59144#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59144","url":"https:\/\/flcube.com\/?p=59144","name":"Hengrui's HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-10T05:24:17+00:00","dateModified":"2026-03-10T05:24:18+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS9531, a novel dual agonist targeting GIPR and GLP-1R, has received NMPA clinical trial approval for the treatment of chronic kidney disease (CKD). The approval marks a strategic expansion of Hengrui's globally proprietary incretin platform beyond its established glycemic control and weight management applications into renal protection, positioning the candidate as a potential multi-indication metabolic-renal therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59144#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59144"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59144#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HRS9531 Wins NMPA Approval for CKD Trial \u2013 Dual GIPR\/GLP-1R Agonist Expands Beyond Diabetes and Obesity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59144"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59144\/revisions"}],"predecessor-version":[{"id":59147,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59144\/revisions\/59147"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}